Héctor F. Escobar-Morreale, MD, PhD; José I. Botella-Carretero, MD; Manuel Gómez-Bueno, MD; José M. Galán, MD; Vivencio Barrios, MD, PhD; José Sancho, MD, PhD
Note: An earlier version of this paper was presented at the Endocrine Society's 85th Annual Meeting in Philadelphia, Pennsylvania, 19–22 June 2003.
Acknowledgments: The authors thank Genoveva González for excellent technical help; Robertas Bunevicius and Carlos Peiró for invaluable advice regarding the tests of quality of life, mood, and psychometric functionality; and Ana Tabuenca for help with power analysis.
Grant Support: By Merck KgaA, Darmstad, Germany. Dr. Botella-Carretero is supported by fellowships from the Consejería de Educación, Comunidad de Madrid (01/0430/01) and from the Fondo de Investigación Sanitaria (01/F072), Instituto de Salud Carlos III, Ministerio de Sanidad y Consumo, Spain.
Potential Financial Conflicts of Interest: Grants received: H.F. Escobar-Morreale (Merck KgaA, Darmstad, Germany).
Requests for Single Reprints: Héctor F. Escobar-Morreale, MD, PhD, Department of Endocrinology, Hospital Ramón y Cajal, Carretera de Colmenar Km 9'1, E-28034 Madrid, Spain; e-mail, firstname.lastname@example.org.
Current Author Addresses: Drs. Escobar-Morreale, Botella-Carretero, and Sancho: Department of Endocrinology, Hospital Ramón y Cajal, Carretera de Colmenar Km 9'1, E-28034 Madrid, Spain.
Drs. Gómez-Bueno and Barrios: Department of Cardiology, Hospital Ramón y Cajal, Carretera de Colmenar Km 9'1, E-28034 Madrid, Spain.
Dr. Galán: Department of Neurophysiology, Hospital Ramón y Cajal, Carretera de Colmenar Km 9'1, E-28034 Madrid, Spain.
Author Contributions: Conception and design: H.F. Escobar-Morreale.
Analysis and interpretation of the data: H.F. Escobar-Morreale, J.I. Botella-Carretero, V. Barrios.
Drafting of the article: H.F. Escobar-Morreale, J.I. Botella-Carretero, M. Gómez-Bueno, J. Gálan, V. Barrios, J. Sancho.
Critical revision of the article for important intellectual content: H.F. Escobar-Morreale, J. Sancho.
Final approval of the article: H.F. Escobar-Morreale, J.I. Botella-Carretero, M. Gómez-Bueno, J. Gálan, V. Barrios, J. Sancho.
Provision of study materials or patients: H.F. Escobar-Morreale, J.I. Botella-Carretero, M. Gómez-Bueno, J. Gálan.
Statistical expertise: H.F. Escobar-Morreale, J.I. Botella-Carretero.
Obtaining of funding: H.F. Escobar-Morreale.
Administrative, technical, or logistic support: H.F. Escobar-Morreale, J. Sancho.
Collection and assembly of data: J.I. Botella-Carretero.
Substituting part of the dose of l-thyroxine with small but supraphysiologic doses of liothyronine in hypothyroid patients has yielded conflicting results.
To evaluate combinations of l-thyroxine plus liothyronine in hypothyroid patients that match the proportions present in normal secretions of the human thyroid gland.
Randomized, double-blind, crossover trial.
Academic research hospital.
28 women with overt primary hypothyroidism.
Crossover trial comparing treatment with l-thyroxine, 100 µg/d (standard treatment), versus treatment with l-thyroxine, 75 µg/d, plus liothyronine, 5 µg/d (combination treatment), for 8-week periods. All patients also received l-thyroxine, 87.5 µg/d, plus liothyronine, 7.5 µg/d (add-on combination treatment), for a final 8-week add-on period.
Primary outcomes included serum thyroid hormone levels, results of quality-of-life and psychometric tests, and patients' preference. Multiple biological thyroid hormone end points were studied as secondary outcomes.
Compared with standard treatment, combination treatment led to lower free thyroxine levels (decrease, 3.9 pmol/L [95% CI, 2.5 to 5.3 pmol/L]), slightly higher serum levels of thyroid-stimulating hormone (increase, 0.62 mU/L [CI, 0.01 to 1.23 mU/L]), and unchanged free triiodothyronine levels. No improvement was observed in the other primary and secondary end points after combination treatment, with the exception of the Digit Span Test, in which the mean backward score and the mean total score increased slightly (0.6 digit [CI, 0.1 to 1.0 digit] and 0.8 digit [CI, 0.2 to 1.4 digits], respectively). The add-on combination treatment resulted in overreplacement. Levels of thyroid-stimulating hormone decreased by 0.85 mU/L (CI, 0.27 to 1.43 mU/L) and serum free triiodothyronine levels increased by 0.8 pmol/L (CI, 0.1 to 1.5 pmol/L) compared with standard treatment; 10 patients had levels of thyroid-stimulating hormone that were below the normal range. Twelve patients preferred combination treatment, 6 patients preferred the add-on combination treatment, 2 patients preferred standard treatment, and 6 patients had no preference (P = 0.015).
Treatment with l-thyroxine, 87.5 µg/d, plus liothyronine, 7.5 µg/d, was an add-on regimen and was not randomized.
Physiologic combinations of l-thyroxine plus liothyronine do not offer any objective advantage over l-thyroxine alone, yet patients prefer combination treatment.
Learn more about subscription options.
Register Now for a free account.
Escobar-Morreale HF, Botella-Carretero JI, Gómez-Bueno M, Galán JM, Barrios V, Sancho J. Thyroid Hormone Replacement Therapy in Primary Hypothyroidism: A Randomized Trial Comparing l-Thyroxine plus Liothyronine with l-Thyroxine Alone. Ann Intern Med. 2005;142:412–424. doi: 10.7326/0003-4819-142-6-200503150-00007
Download citation file:
Published: Ann Intern Med. 2005;142(6):412-424.
Endocrine and Metabolism, Thyroid Disorders.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only